Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs

Table 3 Characteristics of CHB patients who showed non-response to re-treatment with the same oral nucleos(t)ide analog that had induced initial complete virologic response

Patients	Medication	HBeAg status	Baseline DNA level (IU/ml)	Liver cirrhosis	Total treatment^a(months)	Additional treatment^b(months)	Time to relapse^c(months)	Genotypic resistance	Rescue therapy after second treatment failure	Response to rescue therapy
Patient 1	Clevudine	Positive	20,000,000	Negative	13	7	5	rtM204I	Entecavir	Sustained VR
Patient 2	Lamivudine	Negative	2,099,619	Positive	24	18	2	rtM204I	Entecavir	PartialVR
Patient 3	Lamivudine	Negative	257,039	Negative	20	7	3	rtM204I	Entecavir	Sustained VR
Patient 4	Entecavir	Positive	20,000,000	Negative	33	16	6	rtM204I	Entecavir + Adefovir	Partial VR

^aTotal duration of initial oral nucleos(t)ide analog therapy.
^bAdditional treatment duration of initial oral nucleos(t)ide analog therapy after undetectable HBV DNA.
^cTime to relapse after discontinuation of initial oral nucleos(t)ide analog therapy.
VR, virologic response.

ISSN: 1471-2334